CLINICAL TRIALS PROFILE FOR PARLODEL
✉ Email this page to a colleague
All Clinical Trials for PARLODEL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02428946 ↗ | Bromocriptine and Insulin Sensitivity | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A | 2014-10-01 | In this study the investigators will examine the effect of dopamine (bromocriptine) on insulin sensitivity in lean and obese subjects. Furthermore, the investigators will examine whether the timing of bromocriptine administration has influence on insulin sensitivity. To do so, the investigators will include lean and obese subjects who will use 2 times 2 weeks bromocriptine. In randomized order, they will use it in the morning or in the evening. The investigators will examine insulin sensitivity by performing a 7-point oral glucose tolerance test. Furthermore, the investigators will examine energy expenditure and subjects will keep track of their eating behaviour in the 3 days before each study visit. |
| NCT02428933 ↗ | Dopaminergic Effects on Brown Adipose Tissue | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A | 2013-10-01 | In this study the investigators will investigate the effect of dopamine (bromocriptine) on Brown Adipose Tissue in lean, young, healthy males. The investigators will also examine energy expenditure, body temperature and insulin sensitivity as measurements of Brown Adipose Tissue activity. |
| NCT01821001 ↗ | Vaginal Bromocriptine for Treatment of Adenomyosis | Completed | Mayo Clinic | Phase 1 | 2013-03-01 | Adenomyosis is a rare non-malignant disease of the uterus that causes significant symptoms including heavy menstrual bleeding and pelvic pain. The only widely accepted treatment for adenomyosis is hysterectomy. The investigators will use a dopamine agonist, bromocriptine, as a therapy based on animal models of the disease and our prior clinical research to observe any objective improvement in the extent of the disease using Magnetic Resonance Imaging (MRI)and standard measurements for other gynecologic diseases to measure symptomatology. |
| NCT00605683 ↗ | MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist | Completed | Newron | Phase 3 | 2007-11-01 | Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO B, the major DA metabolising enzyme in man. This is a double-blind, placebo-controlled, parallel-group, randomised, multi-centre, multi national, Phase III trial, comparing two doses of safinamide (50 and 100 mg p.o. q.a.m.) versus placebo as add-on therapy to a stable dose of a single dopamine agonist in subjects with early idiopathic Parkinson's Disease. The principal efficacy measure, i.e., change in mean value of UPDRS - Section III total score from baseline to endpoint, was chosen based on regulatory guidance and prior use in other trials in similar populations. |
| NCT00605683 ↗ | MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist | Completed | Newron Pharmaceuticals SPA | Phase 3 | 2007-11-01 | Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO B, the major DA metabolising enzyme in man. This is a double-blind, placebo-controlled, parallel-group, randomised, multi-centre, multi national, Phase III trial, comparing two doses of safinamide (50 and 100 mg p.o. q.a.m.) versus placebo as add-on therapy to a stable dose of a single dopamine agonist in subjects with early idiopathic Parkinson's Disease. The principal efficacy measure, i.e., change in mean value of UPDRS - Section III total score from baseline to endpoint, was chosen based on regulatory guidance and prior use in other trials in similar populations. |
| NCT00650520 ↗ | Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets | Completed | Mylan Pharmaceuticals | Phase 1 | 2007-05-01 | The objective of this study is to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg bromocriptine mesylate tablets, following the administration of a 10 mg dose, under fed conditions. |
| NCT00649168 ↗ | Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2007-04-01 | The objective of this study was to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg bromocriptine mesylate capsules, following the administration of a 10 mg dose, under fed conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Showing 1 to 7 of 7 entries
Clinical Trial Conditions for PARLODEL
Condition Name
Clinical Trial Locations for PARLODEL
Trials by Country
Clinical Trial Progress for PARLODEL
Clinical Trial Phase
Clinical Trial Sponsors for PARLODEL
Sponsor Name
